Compare ADT Inc (ADT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Incyte Corporation — how do they compare? ADT Inc trades at $7.46 (market cap $5.44B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 4.5× ADT Inc's market cap, and ADT Inc pays a 2.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ADT | INCY | |
|---|---|---|
Market Cap | $5.44B | $24.54B |
Sector | Industrials | Health |
52-Week High | $8.85 | $129.93 |
52-Week Low | $6.30 | $81.61 |
Enterprise Value | $13.13B | $20.04B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.33, down 2.4% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong cash flow. Valuation ratios appear attractive with a P/E of 10.35 and EV/EBITDA of 4.93. Recent news highlights a Zacks upgrade to Buy and institutional stake increases.
Outlook is positive due to consistent earnings beats and solid profitability, but risks include high debt levels and competitive pressures. Analysts are generally bullish, with 47% recommending Buy. The stock offers value with growth potential from AI integration and shareholder returns via dividends and buybacks.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
